Natixis Advisors, L.P. Catalyst Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 59,253 shares of CPRX stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,253
Previous 45,637
29.84%
Holding current value
$1.28 Million
Previous $907,000
36.38%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CPRX
# of Institutions
345Shares Held
98.4MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$125 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$67.7 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$65.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.22B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...